InspireMD Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los ingresos de InspireMD aumenten en un 62.8% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	17.1%
Tasa de crecimiento de los ingresos	62.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	12 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Jan 11

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

Feb 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NSPR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	30	N/A	N/A	N/A	1
12/31/2025	11	N/A	N/A	N/A	1
12/31/2024	7	N/A	N/A	N/A	1
9/30/2024	7	-28	-21	-19	N/A
6/30/2024	7	-26	-19	-18	N/A
3/31/2024	6	-23	-17	-17	N/A
12/31/2023	6	-20	-17	-16	N/A
9/30/2023	5	-19	-16	-15	N/A
6/30/2023	5	-19	-17	-16	N/A
3/31/2023	5	-18	-17	-16	N/A
12/31/2022	5	-18	-16	-16	N/A
9/30/2022	6	-18	-16	-15	N/A
6/30/2022	5	-17	-15	-14	N/A
3/31/2022	5	-16	-14	-14	N/A
12/31/2021	4	-15	-14	-13	N/A
9/30/2021	3	-15	-13	-13	N/A
6/30/2021	3	-13	-12	-11	N/A
3/31/2021	2	-12	-10	-10	N/A
12/31/2020	2	-11	-9	-9	N/A
9/30/2020	3	-9	-9	-8	N/A
6/30/2020	3	-9	-7	-7	N/A
3/31/2020	4	-9	-9	-9	N/A
12/31/2019	4	-10	-10	-10	N/A
9/30/2019	4	-10	-10	-10	N/A
6/30/2019	3	-10	-10	-10	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	4	-8	-8	-8	N/A
9/30/2018	4	-11	-8	-8	N/A
6/30/2018	4	-11	N/A	-8	N/A
3/31/2018	3	-12	N/A	-7	N/A
12/31/2017	3	-13	N/A	-8	N/A
9/30/2017	2	-10	N/A	-8	N/A
6/30/2017	2	-10	N/A	-9	N/A
3/31/2017	2	-9	N/A	-8	N/A
12/31/2016	2	-8	N/A	-7	N/A
9/30/2016	2	-9	N/A	-8	N/A
6/30/2016	2	-11	N/A	-7	N/A
3/31/2016	2	-13	N/A	-9	N/A
12/31/2015	2	-16	N/A	-12	N/A
9/30/2015	3	-18	N/A	-14	N/A
6/30/2015	2	-21	N/A	-18	N/A
3/31/2015	2	-24	N/A	-20	N/A
12/31/2014	3	-25	N/A	-19	N/A
9/30/2014	4	-26	N/A	-18	N/A
6/30/2014	5	-23	N/A	-15	N/A
3/31/2014	6	-30	N/A	-12	N/A
12/31/2013	6	-29	N/A	-11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de NSPR es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de NSPR crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de NSPR crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (62.8% al año) de NSPR crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (62.8% al año) de NSPR crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NSPR se prevé que sea elevada dentro de 3 años.

InspireMD Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 12%, EPS upgraded

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Consensus estimates of losses per share improve by 46%

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024

InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director exercised options to buy US$153k worth of stock.

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Insider recently bought US$127k worth of stock

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

Consensus estimates of losses per share improve by 46%

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus revenue estimates decrease by 37%, EPS upgraded

Price target decreased to US$5.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought US$68k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$9.00

Full year 2021 earnings: EPS misses analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully

Insider recently bought US$50k worth of stock

Insider recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

InspireMD: Revolutionizing The Field Of Vascular Stenting

Insider recently bought US$93k worth of stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Earnings beat expectations, revenue disappoints

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: US$0.82

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: US$0.71

New 90-day high: US$0.44

Analysts update estimates